LY6K: A Drug Target / Disease Biomarker (G54742)

Target Name: LY6K

NCBI ID: G54742

LY6K

LY6K: A Drug Target / Disease Biomarker

LY6K, also known as 6-kinase-activating receptor (FKOR), is a protein that is expressed in various tissues and cells throughout the body. It is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Recent studies have identified LY6K as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because LY6K has been shown to be involved in the development and progression of these diseases, and may be a useful target for therapeutic intervention.

One of the key reasons for the potential of LY6K as a drug target is its involvement in cell proliferation. LY6K is a co-factor for several cell cycle kinases, including the B-cell kinase, T-cell kinase, and myeloid kinase. These kinases are involved in the regulation of cell proliferation, and LY6K has been shown to play a role in the growth and survival of various cell types.

In addition to its role in cell proliferation, LY6K has also been shown to be involved in the regulation of cell adhesion. LY6K is a co-factor for the cadherin protein, which is involved in cell-cell adhesion. This suggests that LY6K may be involved in the regulation of cell-cell interactions and may be a useful target for drugs that are designed to disrupt these interactions.

The potential therapeutic applications of LY6K as a drug target are vast and varied. For example, LY6K has been shown to be involved in the development and progression of a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is possible that LY6K may be a useful target for drugs that are designed to inhibit its activity or prevent its formation.

In addition to its potential therapeutic applications, LY6K has also been shown to be a useful biomarker for the diagnosis and monitoring of various diseases. For example, LY6K has been shown to be involved in the regulation of cell proliferation and may be a useful biomarker for the diagnosis and treatment of cancer. It is also possible that LY6K may be involved in the regulation of other biological processes and may be a useful biomarker for a variety of other diseases.

Overall, LY6K is a protein that has the potential to be a useful drug target and biomarker for the treatment of a variety of diseases. Further research is needed to fully understand its role in these processes and to develop effective therapies that can be used to treat a wide range of conditions.

Protein Name: Lymphocyte Antigen 6 Family Member K

Functions: Required for sperm migration into the oviduct and male fertility by controlling binding of sperm to zona pellucida (By similarity). May play a role in cell growth (PubMed:18089789)

The "LY6K Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LY6K comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets